Online Database of Chemicals from Around the World

环磷酰胺
[CAS# 60007-95-6]

供应商
Achemo Scientific Limited 香港 询价快递  
+852 3174-6428
sales@achemo.com
化学品生产商(2010 年起)
Alfa Aesar. 美国 询价快递  
+1 (978) 521-6300
info@alfa.com
化学品生产商
BroadPharm. Inc. 美国 询价快递  
+1 (858) 536-7788
sales@broadpharm.com
化学品生产商
ChemScene LLC 美国 询价快递  
+1 (732) 484-9848
sales@chemscene.com
化学品生产商(2011 年起)
Enamine Ltd. 乌克兰 询价快递  
+380 (44) 537-3218
enamine@enamine.net
化学品生产商(1991 年起)
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
Interbioscreen Ltd. 俄罗斯 询价快递  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
化学品生产商
Princeton BioMolecular Research, Inc. 美国 询价快递  
+1 (732) 355-9920
info@princetonbio.com
化学品生产商(1998 年起)
Ryan Scientific, Inc. 美国 询价快递  
+1 (843)-884-4911
sales@ryansci.com
化学品生产商
TimTec 美国 询价快递  
+1 (302) 292-8500
info@timtec.com
化学品生产商
基本信息
产品名称 环磷酰胺
英文名 Cyclophosphamide
别名 N,N-Bis(2-Chloroethyl)-2-Hydroxy-1,3,2-Oxazaphosphinan-2-Ium-2-Amine; (2R)-N,N-Bis(2-Chloroethyl)-2-Oxo-1-Oxa-3-Aza-2$L^{5}-Phosphacyclohexan-2-Amine; N,N-Bis(2-Chloroethyl)-2-Oxo-1-Oxa-3-Aza-2$L^{5}-Phosphacyclohexan-2-Amine
分子结构 CAS 登录号:60007-95-6, 环磷酰胺
分子式 C7H15Cl2N2O2P
分子量 261.09
CAS 登录号 60007-95-6 (60007-96-7;60030-72-0)
分子行输入简码 SMILES C(N([P]1(NCCCO1)=O)CCCl)CCl
国际化学标识码 InChI 1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
国际化学标识检索码 InChIKey CMSMOCZEIVJLDB-UHFFFAOYSA-N
物理化学性质
密度 1.3±0.1g/cm3 (计算值)
熔点 51°C (实验值)
沸点 336.1±52.0°C at 760 mmHg (计算值)
闪点 157.1±30.7°C (计算值)
溶解度 Soluble to 100 mM in water and to 100 mM in DMSO
安全数据
安全编码 S53;S20;S36;S45;S60  说明
危险类别码 R45;R46;R61;R25  说明
危险品标志 symbol  T  说明
危险品运输编号 UN3464
安全说明 Safety glasses, gloves. Do not breathe dust.
TOXIC
DANGER: POISON, cancer risk, causes liver damage
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Clearance , "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Clearance' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in (ml/min/kg) units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Clearance' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (10+-4), Clavulanate (3.6+-1.0), Enoxaparin (0.3+-0.1), Epoetin Alfa (0.047+-0.017 (0.047-0.092)), Etanercept (0.02), Filgrastim (0.5-0.7), Heparin (1/(0.65 + 0/0.008D) +- 0.1), Interferon Alfa (2.8+-0.6), Interferon Beta (13+-5), Lithium (0.35+-0.11), Mycophenolate (MM: 120-163, MPA: 2.5+-0.4), Prednisolone (1.0+-0.16), Rapacuronium (7-11), Sargramostim (A: 420 ml/min/(m.m), C:49(15-118) ml/min/(m.m)) and Streptokinase (1.7+-0.7) have not been provided here. In all, 301 drugs and their 'Clearance' values are given in the files here.
市场分析报告
请浏览环磷酰胺市场分析报告总目录
相关产品
丁基-delta(9)-四氢大麻酚  3-(二甲基氨基)-2-甲基丙烯  3,3'-[(2-氯-1,4-亚苯基)二次氮基]二...  2,2,4,5-四氟-1,3-二氧戊环  4,5-二氯-2,2-二氟-1,3-二氧戊环  2,2,2-三氯乙基磷酰二氯酸酯  广金钱草内酯  羧基氨基咪唑核苷酸  2-[4-(环己基羰基)苯氧基]-2-甲基丙酸  2-[4-(3-氯苯甲酰基)苯氧基]-2-甲基丙酸  2-[4-(2,6-二氯苯甲酰基)苯氧基]-2-甲...  2-[4-(3,4-二氯苯甲酰基)苯氧基]-2-甲...  2-羟基-3-丁烯酸  4,4'-二甲基-10,10'-联蒽酮  碘替酸